A Review of Drug Therapy in the Management of Covid-19

Authors

  • Dinesh Dhodi

  • Amitrajit Pal

Keywords:

COVID-19, Remdesivir, Favipiravir, Tocilizumab, Hydroxychloroquine, Vitamins, Zinc

Abstract

The wrath of the COVID-19 pandemic has crippled the entire world in a state of a medical emergency. The number of cases has been increasing at an alarming and exponential rate and exhausting the medical resources vastly, at the same time questioning the future of such a deadly pandemic. An amalgamation of medical and non-medical knowledge is being followed globally to flatten the curve. However, without any proven cure at hand, several drugs are being researched into studies like Favipiravir, Remdesivir, Tocilizumab, Hydroxychloroquine, to gain substantial evidence of their use either individually or in combination, supplemented by supportive therapy, vitamins, and zinc, to effectively treat the patients and curb the mortality rate of the population.

How to Cite

A Review of Drug Therapy in the Management of Covid-19. (2020). Global Journal of Medical Research, 20(70), 7-14. https://doi.org/10.34257/GJMRBVOL20IS8PG7

URL: https://medicalresearchjournal.org/index.php/GJMR/article/view/2316

References

Yudong Yin, Richard Wunderink (2018) MERS, SARS and other coronaviruses as causes of pneumonia Respirology. 23(2), 130-137. https://doi.org/10.1111/resp.13196

(2020) The species Severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2. 5, 536-544.

T. Richard (2020) Remdesivir: A Review of Its Discovery and Development Leading to Emergency Use Authorization for Treatment of COVID-19. 6(5), 672-683.

Zaki AM, van S, Bestebroer TM (2012) Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia N Engl J Med. 367(19), 1814-1820. https://doi.org/10.1056/nejmoa1211721

Walls AC, Park YJ, Tortorici MA (2020) Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein Cell. 181(2), 281-292. https://doi.org/10.1016/j.cell.2020.02.058

Furata Y, Komeno T, Nakamura T (2017) Favipiravir (T- 705), a broad spectrum inhibitor of viral RNA polymerase Proc Jpn Acad Ser B Phys Biol Sci 2017. 93(7), 449-463. https://doi.org/10.2183/pjab.93.027

Madelain V, Olivo Nguyen T.H (2016) Ebola virus infection: review of the pharmacokinetic and pharmacodynamic properties of drugs considered for testing in human efficacy trials Clin Pharmacokinet. 55(8), 907-923. https://doi.org/10.1007/s40262-015-0364-1

de E, Feldmann F, Cronin J (2020) Prophylactic and therapeutic remdesivir (GS-5734) treatment in the rhesus macaque model of MERS-CoV infection. 117, 6771-6776.

Sheahan TP, Sims AC, Graham RL (2017) Broadspectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses. 9(396), eaal3653.

Sheahan TP, Sims AC, Leist SR (2020) Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV. 11(1), 222. https://doi.org/10.1038/s41467-019-13940-6

Wang M, Cao R, Zhang L (2020) Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. 30, 269-271.

Duxin Sun (2020) Remdesivir for Treatment of COVID- 19: Combination of Pulmonary and IV Administration May Offer Additional Benefit. 22(4), 77. https://doi.org/10.1208/s12248-020-00459-8

N. Green, R. Ott, R. Isaacs, H. Fang (2008) Cellbased Assays to Identify Inhibitors of Viral Disease. 3, 671−676.

Sheppard M, Laskou F, Stapleton PP, Hadavi S, Dasgupta B (2017) Tocilizumab (actemra). 13, 1972---88.

Zhang S, Li L, Shen A, Chen Y, Qi Z (2020) Rational use of tocilizumab in the treatment of novel coronavirus pneumonia. 40, 511---8.

Levi M (2020) Tocilizumab for severe COVID-19: a promising intervention affecting inflammation and coagulation. 76, 21---2.

Graeme Jones, Changhai Ding (2010) Tocilizumab: a review of its safety and efficacy in rheumatoid arthritis. Clinical medicine insights. 3, CMAMD.S4864. https://doi.org/10.4137/cmamd.s4864

Shi Y, Wang Y, Shao C, Huang J, Gan J, XiaopingH (2020) COVID-19 infection: the perspectives onimmune responses. 27, 1451---4.

Wu SF, Chang CB, Hsu JM, Lu MC, Lai NS, Li C (2017) Hydroxychloroquine inhibits CD154 expression in CD4(+) T lymphocytes of systemic lupus erythematosus through NFAT, but not STAT5, signalling. 19(1), 183. https://doi.org/10.1186/s13075-017-1393-y

van den Borne, BE, B. Dijkmans, H. de Rooij, S. le Cessie, C. Verweij (1997) Chloroquine and hydroxychloroquine equally affect tumor necrosis factor-alpha, interleukin 6, and interferon-gamma production by peripheral blood mononuclear cells. 24, 55-60.

Lotteau V, Teyton L, Peleraux A, Nilsson T, Karlsson L, Schmid SL (1990) Intracellular transport of class II MHC molecules directed by invariant chain. 348, 600-605.

Munster T, Gibbs JP, Shen D, Baethge BA, Botstein GR, Caldwell J (2002) Hydroxychloroquine concentration-response relationships in patients with rheumatoid arthritis. 46, 1460-1469. https://doi.org/10.1002/art.10307

A. Makin, J. Wendon, S. Fitt, B. Portmann, R. Williams (1994) Fulminant hepatic failure secondary to hydroxychloroquine. 35, 569-570. https://doi.org/10.1136/gut.35.4.569

M. Murphy, A. Carmichael (2001) Fatal toxic epidermal necrolysis associated with hydroxychloroquine. 26, 457-458.

https://www.fda.gov/emergency-preparedness-and-response/mcm-legal-regulatory-and-policy-framework/emergency-use-authorization#coviddrugs

F. Njoo, C. Hack, J. Oosting, L. Luyendijk, J. Stilma, A. Kijlstra (1994) C-reactive protein and interleukin-6 are elevated in onchocerciasis patients after ivermectin treatment. 170, 663-8.

Gupta D (2020) Ivermectin: potential candidate for the treatment of Covid 19. https://doi.org/10.1016/j.bjid.2020.06.002

Aránzazu González Canga, Ana Sahagún Prieto, M. Diez Liébana, Nélida Fernández Martínez, Matilde Sierra Vega, Juan García Vieitez (2008) The Pharmacokinetics and Interactions of Ivermectin in Humans-A Mini-review. 10(1), 42-46. https://doi.org/10.1208/s12248-007-9000-9

Clinical India (2020) Randomised controlled trial of ivermectin in hospitalised patients with COVID19. https://ctri.nic.in/Clinicaltrials/pmaindet2

M. Brooks, E. Burtseva, P. Ellery, G. Marsh, A. Lew, A. Slepushkin (2012) Antiviral activity of arbidol, a broad-spectrum drug for use against respiratory viruses, varies according to test conditions. J. Med. 84(1), 170-181. https://doi.org/10.1002/jmv.22234

Zhenwei Wang, Xiaorong Chen, Yunfei Lu, Feifei Chen, Wei Zhang (2020) Clinical characteristics and therapeutic procedure for four cases with 2019 novel coronavirus pneumonia receiving combined Chinese and Western medicine treatment. 14(1), 64-68. https://doi.org/10.5582/bst.2020.01030

N. Lian, H. Xie, S. Lin, J. Huang, J. Zhao, Q. Lin (2020) Umifenovir treatment is not associated with improved outcomes in patients with coronavirus disease 2019: a retrospective study. 26(7), 917-921. https://doi.org/10.1016/j.cmi.2020.04.026

World Health Organization Clinical management of severe acute respiratory infection when novel coronavirus (nCoV) infection is suspected. https://www.who.int/publications-detail/clinical-management-of-severe-acute-respiratory-infection-when-novelcoronavirus-(ncov)-infection-is-suspected

Moller Alhazzani W, Loeb Arabi Y.M, Rhodes Gong M.N (2020) Surviving Sepsis Campaign: guidelines on the management of critically ill adults with Coronavirus Disease 2019 (COVID- 19) Intensive Care Med. 46(5), 854-887. https://doi.org/10.1007/s00134-020-06022-5

J. Zaroob, D. Cender (1998) A different look at corticosteroids Am Fam Physician. 58(2), 443-450.

Awadhesh Singh, Sujoy Majumdar, Ritu Singh, Anoop Misra (2020) Role of corticosteroid in the management of COVID-19: A systemic review and a Clinician's perspective. 14(5), 971-978. https://doi.org/10.1016/j.dsx.2020.06.054

Bikdeli B, Madhavan MV, Jimenez D, Chuich T, Dreyfus I, Driggin E (2020) COVID-19 and thrombotic or thromboembolic disease: implications for prevention, antithrombotic therapy, and follow-up. S0735109720350087. https://doi.org/10.1016/j.jacc.2020.04.031

Ling Lin, Lianfeng Lu, Wei Cao, Taisheng Li (2020) Hypothesis for potential pathogenesis of SARS- CoV-2 infection-a review of immune changes in patients with viral pneumonia. 9(1), 727-732.

Ibs K.H., Rink L. (2003) Zinc-altered immune function. 133(5 Suppl 1), 1452S-1456S.

Silke Overbeck, Lothar Rink, Hajo Haase (2008) Modulating the immune response by oral zinc supplementation: a single approach for multiple diseases. 56(1), 15-30. https://doi.org/10.1007/s00005-008-0003-8

National Institutes of Health (2020) National Institutes of Health. 43. https://ods.od.nih

Yun-Fang Zhou, Bang-An Luo, Lu-Lu Qin (2019) The association between vitamin D deficiency and communityacquired pneumonia: A meta-analysis of observational studies. 98(38), e17252. https://doi.org/10.1097/md.0000000000017252

Harri Hemilä, Elizabeth Chalker (2019) Vitamin C Can Shorten the Length of Stay in the ICU: A Meta-Analysis. 11(4), 708. https://doi.org/10.3390/nu11040708

Huang F, Zhang C, Liu Q, Zhao Y, Zhang Y (2020) Identification of amitriptyline HCl, flavin adenine dinucleotide, azacitidine and calcitriol as repurposing drugs for influenza A H5N1 virus-induced lung injury. 16(3), e1008341. https://doi.org/10.1371/journal.ppat.1008341

Jiménez MA, Jiménez JL, Fernández A, Brochado O, Bellón JM (2019) VDR rs2228570 polymorphism is related to nonprogression to AIDS in antiretroviral therapy naïve HIVinfected patients. 8(3), 311.

Komolmit P, Charoensuk K, Thanapirom K, Suksawatamnuay S, Thaimai P, Chi-rathaworn C (2017) Correction of vitamin D deficiency facilitated suppressionof IP-10 and DPP IV levels in patients with chronic hepatitis C: a randomiseddoubleblinded, placebo-control trial. 12.

Reinhold Vieth, Samantha Kimball, Amanda Hu, Paul Walfish (2004) Vieth R, Kimball S, Hu A, Walfish PG. Randomized comparison of the effects of the vitamin D3 adequate intake versus 100 mcg (4000 IU) per day on biochemical responses and the wellbeing of patients. 3(1), 8. https://doi.org/10.1186/1475-2891-3-8

H. Bischoff-Ferrari, A. Shao, B. Dawson-Hughes, J. Hathcock, E. Giovannucci, W. Willett Benefit-risk assessment of vitamin D supplementation. 21, 1121-1132.

Cheng Y, Wong R, Soo YO (2005) Use of convalescent plasma therapy in SARS patients in Hong Kong. 24(1), 44-46. https://doi.org/10.1007/s10096-004-1271-9

Naveen Salins, Sushma Bhatnagar (2020) Symptom Management and Supportive Care of Serious COVID-19 Patients and their Families in India. 24(6), 435-444. https://doi.org/10.5005/jp-journals-10071-23400

A Review of Drug Therapy in the Management of Covid-19

Published

2020-11-06

How to Cite

A Review of Drug Therapy in the Management of Covid-19. (2020). Global Journal of Medical Research, 20(70), 7-14. https://doi.org/10.34257/GJMRBVOL20IS8PG7